GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » General and Admin. Expense

Thiogenesis Therapeutics (TSXV:TTI) General and Admin. Expense : C$1.16 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Thiogenesis Therapeutics's General and Admin. Expense for the three months ended in Sep. 2024 was C$0.27 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2024 was C$1.16 Mil.


Thiogenesis Therapeutics General and Admin. Expense Historical Data

The historical data trend for Thiogenesis Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics General and Admin. Expense Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23
General and Admin. Expense
0.06 0.10 0.09 0.22 1.04

Thiogenesis Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.34 0.28 0.26 0.27

Thiogenesis Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thiogenesis Therapeutics General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Thiogenesis Therapeutics Business Description

Traded in Other Exchanges
Address
4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Executives
Vincent P. Stanton 10% Security Holder

Thiogenesis Therapeutics Headlines